Marlena S. Fejzo

ORCID: 0000-0001-6800-687X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pregnancy and Medication Impact
  • Electrolyte and hormonal disorders
  • Pharmacological Effects and Toxicity Studies
  • Pregnancy and preeclampsia studies
  • Maternal Mental Health During Pregnancy and Postpartum
  • GDF15 and Related Biomarkers
  • RNA modifications and cancer
  • Ubiquitin and proteasome pathways
  • Cancer-related gene regulation
  • Reproductive System and Pregnancy
  • Ovarian cancer diagnosis and treatment
  • Molecular Biology Techniques and Applications
  • Gene expression and cancer classification
  • Cancer-related molecular mechanisms research
  • RNA Research and Splicing
  • Genomics and Chromatin Dynamics
  • Folate and B Vitamins Research
  • Peptidase Inhibition and Analysis
  • HER2/EGFR in Cancer Research
  • Uterine Myomas and Treatments
  • Gestational Trophoblastic Disease Studies
  • Advanced Biosensing Techniques and Applications
  • Social Policies and Family
  • Lung Cancer Treatments and Mutations
  • Ion Transport and Channel Regulation

University of California, Los Angeles
2012-2025

University of Southern California
2012-2024

Southern California University for Professional Studies
2024

Keck Hospital of USC
2022

Southern California University of Health Sciences
2022

Cambridge University Press
2011

New York University Press
2011

Chitose Institute of Science and Technology
2011

John Radcliffe Hospital
2011

Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2011

HER2 amplification occurs in 18% to 27% of gastric and gastroesophageal junction cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR HER2. To explore the role HER family biology upper gastrointestinal cancers, we evaluated effect lapatinib, erlotinib, trastuzumab panel molecularly characterized human cancer cell lines xenografts.EGFR protein expression were determined 14 status was assessed by fluorescent situ hybridization. Dose-response curves generated...

10.1158/1078-0432.ccr-09-1112 article EN Clinical Cancer Research 2010-02-24

Hyperemesis gravidarum (HG), severe nausea and vomiting of pregnancy, occurs in 0.3-2% pregnancies is associated with maternal fetal morbidity. The cause HG remains unknown, but familial aggregation results twin studies suggest that understanding the genetic contribution essential for comprehending disease etiology. Here, we conduct a genome-wide association study (GWAS) binary (HG) ordinal (severity vomiting) phenotypes pregnancy complications. Two loci, chr19p13.11 chr4q12, are significant...

10.1038/s41467-018-03258-0 article EN cc-by Nature Communications 2018-03-21

Objective. Hyperemesis gravidarum (HG) can be accompanied by severe physical and emotional distress. Most studies have focused on the psychological stress associated with this condition during affected pregnancy. This study explores posttraumatic symptoms (PTSS) negative life outcomes following HG pregnancies.Methods. A total of 610 women (HG = 377 control 233) were recruited completed an online survey. χ-square analyses used to compare groups various outcome variables.Results. Eighteen...

10.3109/14767058.2011.582904 article EN The Journal of Maternal-Fetal & Neonatal Medicine 2011-06-03

Abstract Uterine leiomyomata are thought to be monoclonal neoplasms. Accordingly, investigations of clonality with G6PD isoforms used as a marker for X chromosome inactivation have suggested independent origins multiple tumors within individual uteri. However, results from recent study assessing methylation differences between DNA active and inactive chromosomes been interpreted suggest that may arise common precursor. We examined the 36 16 patients by analyzing indicated status X‐linked...

10.1002/gcc.2870110102 article EN Genes Chromosomes and Cancer 1994-09-01

To report the weight loss and associated symptoms experienced by a large cohort of women with hyperemesis gravidarum (HG).Data were obtained from an HG website registry, where recruited on-line. Respondents included if they at least 1 live birth>27 weeks' gestation. Extreme was defined as >15% prepregnancy weight.Of 819 surveyed, 214 (26.1%) met criteria for extreme loss. These twice likely to be Hispanic or nonwhite. (p<0.001) indicators severity HG, such hospitalization use parenteral...

10.1089/jwh.2009.1431 article EN Journal of Women s Health 2009-12-01

In this study, we explore the therapeutic potential of lapatinib a selective inhibitor both EGFR and HER2 tyrosine kinases for treatment endometrial cancer. The effect on tumour cell growth receptor activation was studied in panel human cancer lines. Candidate molecular markers predicting sensitivity were assessed by baseline gene expression profiling, ELISA, western blot analyses. Multiple drug effect/combination index (CI) isobologram analysis used to study interactions between...

10.1038/sj.bjc.6604278 article EN cc-by-nc-sa British Journal of Cancer 2008-03-01

Objective Hyperemesis gravidarum, severe nausea and vomiting in pregnancy, occurs up to 2% of pregnancies leads significant weight loss, dehydration, electrolyte imbalance, ketonuria. It is associated with both maternal fetal morbidity. Familial aggregation studies twin suggest a genetic component. In recent GWAS, we showed that placentation, appetite, cachexia genes GDF15 IGFBP7 are linked hyperemesis gravidarum (HG). The purpose this study determine whether upregulated HG patients. Methods...

10.1055/a-0830-1346 article DE cc-by Geburtshilfe und Frauenheilkunde 2019-02-26

A genome-wide association study (GWAS) linked the placenta and appetite hormone gene GDF15 to hyperemesis gravidarum (HG). This paradigm-changing finding has shifted field away from prevailing hypotheses, but more evidence is needed. was performed identify coding variants in addition non-coding implicated by GWAS.Case-control research a university setting.Case-control study.Hyperemesis cases requiring intravenous fluid treatment for disease (n = 926) controls with normal or no nausea...

10.1111/1471-0528.17129 article EN BJOG An International Journal of Obstetrics & Gynaecology 2022-02-26

Uterine leiomyomata are the most common pelvic tumors in women and indication for more than 200,000 hysterectomies annually United States. Rearrangement of chromosome 12 bands q14-q15 is characteristic uterine other benign mesenchymal tumors, we identified a yeast artificial (YAC) spanning translocation breakpoints leiomyoma, pulmonary chondroid hamartoma, lipoma. Recently, demonstrated that HMGIC, which an architectural factor mapping within YAC, disrupted lipomas, resulting novel fusion...

10.1002/(sici)1098-2264(199609)17:1<1::aid-gcc1>3.0.co;2-0 article EN Genes Chromosomes and Cancer 1996-09-01

Abstract Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as separate bands 8q21 and 8q24 has been reported independent studies. Since tumor protein D52 ( TPD52 ) identified a amplification breast prostate carcinoma, we compared expression normal epithelium n = 9), benign serous adenomas 11), borderline tumors 6) invasive carcinomas major histologic subtypes 57) using immunohistochemistry. These analyses revealed that all samples...

10.1002/ijc.21250 article EN International Journal of Cancer 2005-06-28

Objective: To identify factors associated with prolonged Hyperemesis Gravidarum (HG). Study Design: About 395 women completed a survey regarding pre-existing conditions, treatments and outcomes. Responses were compared using two-sided t-tests or the F-test. Results: Participants HG are slightly younger weigh more. Pre-existing include allergies restrictive diet. Prolonged is hematemesis, dizziness, fainting antiemetic treatment. Following pregnancy, those reported more posttraumatic stress,...

10.3109/14767058.2011.598588 article EN The Journal of Maternal-Fetal & Neonatal Medicine 2011-09-15

Nausea and vomiting (NVP) affect most pregnant women. At the severe end of clinical spectrum, hyperemesis gravidarum (HG) can be life-threatening. The condition is fraught with misconceptions that have slowed progress left women undertreated. Herein, recent scientific advances are presented dispel common myths associated HG related to maternal/offspring outcomes, etiology, evolution. There now strong evidence (i) poor (ii) a cause NVP has been identified, (iii) likely protective evolutionary...

10.1016/j.molmed.2024.04.006 article EN other-oa Trends in Molecular Medicine 2024-05-22
Coming Soon ...